LMO 4 is an essential mediator of ErbB 2 / HER 2 / Neu-induced breast cancer cell cycle progression
暂无分享,去创建一个
J. Visvader | B. Andersen | M. Landis | Ra | D. Seachrist | ME Montañez-Wiscovich | Keri
[1] R. Kucherlapati,et al. Genetic Mechanisms in Apc-Mediated Mammary Tumorigenesis , 2009, PLoS genetics.
[2] Hae-Ahm Lee,et al. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation. , 2007, European journal of pharmacology.
[3] K. Lam,et al. The LIM-only factor LMO4 regulates expression of the BMP7 gene through an HDAC2-dependent mechanism, and controls cell proliferation and apoptosis of mammary epithelial cells , 2007, Oncogene.
[4] G. Sumara,et al. A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating mitotic progression and completion of cytokinesis in human cells. , 2007, Developmental cell.
[5] J. Bergh,et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.
[6] Jin Xu,et al. LMO4 mRNA stability is regulated by extracellular ATP in F11 cells. , 2007, Biochemical and biophysical research communications.
[7] L. Prakash,et al. ELA1 and CUL3 Are Required Along with ELC1 for RNA Polymerase II Polyubiquitylation and Degradation in DNA-Damaged Yeast Cells , 2007, Molecular and Cellular Biology.
[8] Gregory E. J. Harding,et al. Osteopontin localizes to the nucleus of 293 cells and associates with polo-like kinase-1. , 2007, American journal of physiology. Cell physiology.
[9] Joshy George,et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.
[10] Yusuke Nakamura,et al. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. , 2006, International journal of oncology.
[11] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[12] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[13] Robert D Cardiff,et al. The transcriptional repressor Snail promotes mammary tumor recurrence. , 2005, Cancer cell.
[14] R. Keri,et al. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-β signaling in ErbB2/Neu-induced tumors from transgenic mice , 2005, Oncogene.
[15] J. Visvader,et al. Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development , 2005, Oncogene.
[16] J. Visvader,et al. Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Visvader,et al. The LIM Domain Protein Lmo4 Is Highly Expressed in Proliferating Mouse Epithelial Tissues , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[18] E. Andrechek,et al. Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth , 2005, Oncogene.
[19] M. Gorospe,et al. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs , 2004, The EMBO journal.
[20] B. Andersen,et al. Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in mice , 2004, Oncogene.
[21] J. Visvader,et al. Mutational analysis of the LMO4 gene, encoding a BRCA1‐interacting protein, in breast carcinomas , 2003, International journal of cancer.
[22] S. Elledge,et al. BTB proteins are substrate-specific adaptors in an SCF-like modular ubiquitin ligase containing CUL-3 , 2003, Nature.
[23] Sergio Wittlin,et al. Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. , 2003, Genomics.
[24] D. Stern,et al. ErbBs in mammary development. , 2003, Experimental cell research.
[25] C. Arteaga,et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. , 2002, Cancer research.
[26] Richard Simon,et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[27] Xin Yu,et al. The LIM Domain Protein LMO4 Interacts with the Cofactor CtIP and the Tumor Suppressor BRCA1 and Inhibits BRCA1 Activity* , 2002, The Journal of Biological Chemistry.
[28] Spyro Mousses,et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. , 2002, Cancer research.
[29] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Visvader,et al. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] A. Lenferink,et al. ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways. , 2001, Cancer research.
[32] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[33] D. Watkins-Chow,et al. Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility. , 2001, Human molecular genetics.
[34] Myriam Gorospe,et al. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation , 2000, The EMBO journal.
[35] R. Keri,et al. An NF-Y Binding Site Is Important for Basal, but Not Gonadotropin-releasing Hormone-stimulated, Expression of the Luteinizing Hormone β Subunit Gene* , 2000, The Journal of Biological Chemistry.
[36] W. Muller,et al. Signal transduction in mammary tumorigenesis: a transgenic perspective , 2000, Oncogene.
[37] Y. Yarden,et al. Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.
[38] M. Rosenfeld,et al. Mouse deformed epidermal autoregulatory factor 1 recruits a LIM domain factor, LMO-4, and CLIM coregulators. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] T. Rabbitts,et al. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes. , 1998, Genes & development.
[40] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[41] M. Sliwkowski,et al. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness. , 1996, Cancer research.
[42] N. Hynes,et al. Epidermal Growth Factor-related Peptides Activate Distinct Subsets of ErbB Receptors and Differ in Their Biological Activities (*) , 1996, The Journal of Biological Chemistry.
[43] D. Caporossi,et al. Characteristic chromosomal fragility of human embryonic cells exposed in vitro to aphidicolin , 1995, Human Genetics.
[44] V. Sánchez-Margalet,et al. Role of phosphatidylinositol-3-kinase in insulin receptor signaling: studies with inhibitor, LY294002. , 1994, Biochemical and biophysical research communications.
[45] Y. Yarden,et al. A single autophosphorylation site confers oncogenicity to the Neu/ErbB‐2 receptor and enables coupling to the MAP kinase pathway. , 1994, The EMBO journal.
[46] M. Gossen,et al. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. , 1994, Molecular and cellular biology.
[47] R. Cardiff,et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[48] Y. Yarden,et al. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation. , 1992, The Journal of biological chemistry.
[49] A. Ullrich,et al. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma. , 1991, The EMBO journal.
[50] Tony Hunter,et al. Isolation of a human cyclin cDNA: Evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2 , 1989, Cell.
[51] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[52] M. Kraus,et al. Overexpression of the EGF receptor‐related proto‐oncogene erbB‐2 in human mammary tumor cell lines by different molecular mechanisms. , 1987, The EMBO journal.
[53] N. Nomura,et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.
[54] J. Mosley,et al. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. , 2008, BMC medical genomics.
[55] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.